GAITHERSBURG, Md., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the “Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today that, following a recent meeting with the Coverage and Analysis Group of the Centers for Medicare & Medicaid Services (“CMS”), the Company has gained greater clarity on the necessary conditions that can lead to a favorable reimbursement determination for its autologous platelet rich plasma (“PRP”) gel in wound management.
